Exact Sciences Corporation logo
Exact Sciences Corporation EXAS
$ 103.36 0.0%

Annual report 2025
added 02-13-2026

report update icon

Exact Sciences Corporation Balance Sheet 2011-2026 | EXAS

Annual Balance Sheet Exact Sciences Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-916 M -560 M -526 M -207 M -283 M -137 M 651 M 528 M -73 M -44.1 M -36.1 M 167 M 109 M 82.4 M 22.8 M

Long Term Debt

6.4 M 13.2 M 50 M 7.4 M 12.5 M 1.34 B 828 M 689 M 4.27 M 4.63 M 4.85 M 1 M 1 M 1 M 1 M

Long Term Debt Current

33.6 M 27.4 M 29.4 M 28.4 M 19.7 M 11.5 M 7.89 M 8 K 182 K - - - - - -

Total Non Current Liabilities

- - - - - - 981 M 706 M 10 M 11.1 M 10.7 M 5.12 M 3.56 M 2.07 M 5.48 M

Total Current Liabilities

641 M 732 M 515 M 413 M 517 M 576 M 236 M 137 M 68.1 M 30.7 M 26.7 M 17.5 M 7.75 M 11.5 M 7.98 M

Total Liabilities

3.46 B 3.53 B 3.33 B 3.18 B 3.3 B 2.1 B 1.22 B 843 M 78.1 M 41.7 M 37.4 M 22.6 M 11.3 M 13.5 M 13.5 M

Deferred Revenue

- - - - - - - - - - - - - - 4.14 M

Retained Earnings

-4.71 B -4.5 B -3.47 B -3.27 B -2.64 B -1.97 B -1.12 B -1.04 B -861 M -746 M -579 M -421 M -321 M -274 M -222 M

Total Assets

5.86 B 5.93 B 6.47 B 6.23 B 6.68 B 4.93 B 3.51 B 1.52 B 599 M 377 M 364 M 312 M 147 M 112 M 97 M

Cash and Cash Equivalents

956 M 601 M 605 M 242 M 315 M 1.49 B 177 M 160 M 77.5 M 48.9 M 41.1 M 58.1 M 12.9 M 13.3 M 35.8 M

Book Value

2.4 B 2.4 B 3.15 B 3.04 B 3.39 B 2.82 B 2.29 B 681 M 520 M 335 M 327 M 289 M 135 M 98.6 M 83.5 M

Total Shareholders Equity

2.4 B 2.4 B 3.15 B 3.04 B 3.39 B 2.24 B 2.29 B 681 M 520 M 335 M 327 M 289 M 135 M 98.6 M 83.5 M

All numbers in USD currency

Quarterly Balance Sheet Exact Sciences Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

7.8 M 9.3 M 11 M 13.2 M 14.8 M 15 M 13.1 M 7.5 M 8.4 M 7.7 M 6.8 M 7.4 M 8 M - 11.6 M 12.5 M 13.2 M 13.1 M 13.2 M 23.8 M 14 M 14 M 14 M 24 M 200 K 804 M 24.8 M 24.5 M 17.1 M 878 K 24.5 M 4.27 M 4.27 M 4.27 M 4.27 M 4.63 M 4.63 M 4.63 M 4.63 M 4.79 M 4.79 M 4.79 M 4.79 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M

Total Liabilities

3.4 B 3.33 B 3.31 B 3.53 B 3.54 B 3.48 B 3.24 B 3.33 B 3.3 B 3.3 B 3.25 B 3.18 B 3.2 B - 3.23 B 3.3 B 3.2 B 3.17 B 3.09 B 2.69 B 2.69 B 2.69 B 2.69 B 1.22 B 1.22 B 1.22 B 1.22 B 843 M 843 M 843 M 843 M 78.1 M 78.1 M 78.1 M 78.1 M 41.7 M 41.7 M 41.7 M 41.7 M 37.2 M 37.2 M 37.2 M 37.2 M 23.8 M 23.8 M 23.8 M 23.8 M 11.3 M - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - 2.3 M - 1.3 M 1 M 18.7 M 28.7 M 39.8 M 25 M 25 M 25 M 25 M 600 K 600 K 600 K 400 K 500 K 500 K 500 K 500 K 200 K 200 K 200 K 200 K - - - - - - - - - - - - 294 K 294 K 294 K 294 K 4.14 M 4.14 M 4.14 M 4.14 M 4.14 M 4.14 M 4.14 M 4.14 M

Retained Earnings

-4.62 B -4.6 B -4.6 B -4.5 B -3.63 B -3.6 B -3.58 B -3.47 B -3.42 B -3.42 B -3.34 B -3.27 B -3.14 B - -2.82 B -2.64 B -2.42 B -2.25 B -2.08 B -2.05 B -2.05 B -2.05 B -2.05 B -1.12 B -1.12 B -1.12 B -1.12 B -1.04 B -1.04 B -1.04 B -1.04 B -861 M -861 M -861 M -861 M -746 M -746 M -746 M -746 M -579 M -579 M -579 M -579 M -421 M -421 M -421 M -421 M -321 M -321 M -321 M -321 M -274 M -274 M -274 M -274 M -222 M -222 M -222 M -222 M

Total Assets

5.9 B 5.8 B 5.71 B 5.93 B 6.75 B 6.67 B 6.38 B 6.47 B 6.42 B 6.36 B 6.3 B 6.23 B 6.31 B - 6.49 B 6.68 B 6.65 B 6.72 B 6.73 B 4.93 B 4.93 B 4.93 B 4.93 B 3.51 B 3.51 B 3.51 B 3.51 B 1.52 B 1.52 B 1.52 B 1.52 B 599 M 599 M 599 M 599 M 377 M 377 M 377 M 377 M 364 M 364 M 364 M 364 M 313 M 313 M 313 M 313 M 147 M 147 M 147 M 147 M 112 M 112 M 112 M 112 M 97 M 97 M 97 M 97 M

Cash and Cash Equivalents

789 M 657 M 347 M 601 M 589 M 530 M 347 M 605 M 595 M 604 M 421 M 242 M 235 M 213 M 190 M 315 M 274 M 364 M 1.1 B 1.49 B 1.49 B 1.49 B 1.49 B 177 M 177 M 177 M 177 M 160 M 160 M 160 M 160 M 77.5 M 77.5 M 77.5 M 77.5 M 48.9 M 48.9 M 48.9 M 48.9 M 41.1 M 41.1 M 41.1 M 41.1 M 58.1 M 58.1 M 58.1 M 58.1 M 12.9 M 12.9 M 12.9 M 12.9 M 12.9 M 13.3 M 13.3 M 13.3 M 35.8 M 35.8 M 35.8 M 35.8 M

Book Value

2.5 B 2.47 B 2.4 B 2.4 B 3.21 B 3.19 B 3.13 B 3.15 B 3.12 B 3.06 B 3.06 B 3.04 B 3.11 B - 3.26 B 3.39 B 3.46 B 3.56 B 3.65 B 2.24 B 2.24 B 2.24 B 2.24 B 2.29 B 2.29 B 2.29 B 2.29 B 681 M 681 M 681 M 681 M 520 M 520 M 520 M 520 M 335 M 335 M 335 M 335 M 327 M 327 M 327 M 327 M 289 M 289 M 289 M 289 M 135 M 147 M 147 M 147 M 112 M 112 M 112 M 112 M 97 M 97 M 97 M 97 M

Total Shareholders Equity

2.5 B 2.47 B 2.4 B 2.4 B 3.21 B 3.19 B 3.13 B 3.15 B 3.12 B 3.06 B 3.06 B 3.04 B 3.11 B 3.21 B 3.26 B 3.39 B 3.46 B 3.56 B 3.65 B 2.24 B 2.24 B 2.24 B 2.24 B 1.96 B 2.29 B 2.29 B 2.29 B 447 M 681 M 681 M 681 M 520 M 520 M 520 M 520 M 335 M 335 M 335 M 335 M 327 M 327 M 327 M 327 M 289 M 289 M 289 M 289 M 135 M 135 M 135 M 135 M 98.6 M 98.6 M 98.6 M 98.6 M 83.5 M 83.5 M 83.5 M 83.5 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Exact Sciences Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Diagnostics research

Issuer Price % 24h Market Cap Country
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.86 -3.38 % $ 92.8 K usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Agilent Technologies Agilent Technologies
A
$ 118.89 0.64 % $ 36.1 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 13.75 -3.17 % $ 416 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 107.73 -0.5 % $ 8.89 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 636.84 0.02 % $ 51.2 B usaUSA
Illumina Illumina
ILMN
$ 130.15 -2.06 % $ 20.7 B usaUSA
Celcuity Celcuity
CELC
$ 108.05 -0.24 % $ 4.26 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Castle Biosciences Castle Biosciences
CSTL
$ 27.48 -1.84 % $ 763 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 283.25 -1.05 % $ 23.6 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 79.36 4.01 % $ 5.36 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Charles River Laboratories International Charles River Laboratories International
CRL
$ 175.2 -1.93 % $ 8.68 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 318.91 -0.31 % $ 27.2 B schweizSchweiz
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 5.21 3.89 % $ 482 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 9.59 0.89 % $ 1.23 B usaUSA
Natera Natera
NTRA
$ 208.22 4.02 % $ 20.5 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.52 -6.17 % $ 456 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Precipio Precipio
PRPO
$ 24.7 0.08 % $ 32.1 M usaUSA
Biodesix Biodesix
BDSX
$ 15.67 -0.51 % $ 2.03 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 6.82 -17.66 % $ 285 M usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 15.74 -1.06 % $ 4.47 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 38.17 -2.28 % $ 1.94 B usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.12 -2.19 % $ 1.42 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 208.58 -0.79 % $ 23.2 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 204.29 -0.83 % $ 146 B usaUSA
Bioventus Bioventus
BVS
$ 8.78 0.11 % $ 550 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 10.3 -4.19 % $ 292 M israelIsrael
DexCom DexCom
DXCM
$ 72.86 -1.24 % $ 28.4 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 507.94 -0.1 % $ 191 B usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 47.14 2.72 % $ 2.82 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 24.01 -6.38 % $ 254 M chinaChina
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.2 -2.22 % $ 19.2 M singaporeSingapore
CareDx, Inc CareDx, Inc
CDNA
$ 18.74 -0.03 % $ 999 M usaUSA
Waters Corporation Waters Corporation
WAT
$ 311.27 1.35 % $ 18.5 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Guardant Health Guardant Health
GH
$ 94.75 2.73 % $ 11.9 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 173.82 -0.27 % $ 29.9 B usaUSA